TCL Archive Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials. October 15, 2004
TCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study December 26, 2014
TCL Archive In Brief – Control Of Many Cancer Forms By End Of The Century, Frederickson Tells House Committee April 6, 1979